Company intelligence / Profile preview

Source Concord Cell Gene Engineering

China

Ownership: Private
Development stage: Other

Overview

Source Concord is actively developing stem cell therapies with a regulatory submission for umbilical cord mesenchymal stem cells for SLE treatment registered and formally accepted by China's State Food and Drug Administration (CFDA)[2]. The company acquired a 13% stake in Beike Biotechnology in December 2014 to strengthen its stem cell and immunotherapy capabilities[2].

Therapeutic areas: OncologyImmunology
Modalities: Cell therapyStem cell therapyGene therapy
Industry: Biotech

Partnerships

Beike Biotechnology (13% stake acquired in 2014)[2]BGI (through Beike partnership)[2]Altor BioScience (through Beike's cancer immunotherapy collaboration)[2]

Beyond the preview

Go deeper on Source Concord Cell Gene Engineering.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Source Concord Cell Gene Engineering.

Explore the full profile